{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:20:06Z","timestamp":1791883206960,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.cllc.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T18:49:24Z","timestamp":1675882164000},"page":"376-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2\u2013IA3 EGFR-Mutated NSCLC: ADAURA2"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8836-1027","authenticated-orcid":false,"given":"Yasuhiro","family":"Tsutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon","family":"van der Gronde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2023.02.002_bib0001","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1183\/09059180.00003913","article-title":"Surgery for nonsmall cell lung cancer","volume":"22","author":"Lang-Lazdunski","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"Suppl 7","key":"10.1016\/j.cllc.2023.02.002_bib0002","doi-asserted-by":"crossref","first-page":"vii196","DOI":"10.1093\/annonc\/mdq376","article-title":"Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?","volume":"21","author":"Le Chevalier","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0003","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN guidelines insights: non\u2013small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines","volume":"19","author":"Ettinger","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cllc.2023.02.002_bib0004","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1200\/JCO.2005.09.017","article-title":"Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer","volume":"23","author":"Hamada","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jjco\/hyy165","article-title":"Pattern of care in adjuvant therapy for resected stage I non-small cell lung cancer: real-world data from Japan","volume":"49","author":"Yoh","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0006","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/JTO.0000000000000320","article-title":"Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters","volume":"9","author":"Peters","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.31892","article-title":"Association of clinicopathologic and molecular tumor features with recurrence in resected early-stage epidermal growth factor receptor-positive non-small cell lung cancer","volume":"4","author":"Saw","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cllc.2023.02.002_bib0008","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.athoracsur.2020.05.041","article-title":"Clinical impacts of EGFR mutation status: analysis of 5780 surgically resected lung cancer cases","volume":"111","author":"Suda","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cllc.2023.02.002_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2020.04.012","article-title":"Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification","volume":"145","author":"Isaka","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.02.002_bib0010","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.21037\/jtd.2019.05.79","article-title":"Prognosis after wedge resection in patients with 8(th) edition TNM stage IA1 and IA2 non-small cell lung cancer","volume":"11","author":"Moon","year":"2019","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.cllc.2023.02.002_bib0011","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jtcvs.2022.01.025","article-title":"The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma","volume":"164","author":"Tsutani","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.cllc.2023.02.002_bib0012","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis","volume":"15","author":"Ahn","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2023.02.002_bib0014","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.02.002_bib0015","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.annonc.2020.08.2100","article-title":"Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis","volume":"31","author":"Papadimitrakopoulou","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0016","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.02.002_bib0017","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0018","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2023.02.002_bib0019","doi-asserted-by":"crossref","unstructured":"Herbst R., Wu Y.-L., John T., et al., Adjuvant osimertinib for resected EGFR-mutated stage IB\u2012IIIA NSCLC: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023 Jan 31;JCO2202186. doi:10.1200\/JCO.22.02186. Online ahead of print.","DOI":"10.1200\/JCO.22.02186"},{"key":"10.1016\/j.cllc.2023.02.002_bib0020","unstructured":"AstraZeneca, Tagrisso\u00ae (Osimertinib). Prescribing Information."},{"key":"10.1016\/j.cllc.2023.02.002_bib0021","unstructured":"AstraZeneca, Tagrisso\u00ae (Osimertinib). Summary of Product Characteristics."},{"key":"10.1016\/j.cllc.2023.02.002_bib0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0023","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jtho.2020.06.001","article-title":"A grading system for invasive pulmonary adenocarcinoma: a proposal from the International Association for the Study of Lung Cancer Pathology Committee","volume":"15","author":"Moreira","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0024","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2023.02.002_bib0025","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/annonc\/mdz189","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0026","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/j.cllc.2015.12.013","article-title":"Risk factors for local and distant recurrence after surgical treatment in patients with non-small-cell lung cancer","volume":"17","author":"Dziedzic","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2023.02.002_bib0027","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22938","article-title":"Prognostic factors for survival of stage I non\u2013small cell lung cancer patients","volume":"110","author":"Ou","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2023.02.002_bib0028","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/fon.12.25","article-title":"Differences in outcome and toxicity between Asian and Caucasian patients with lung cancer treated with systemic therapy","volume":"8","author":"Soo","year":"2012","journal-title":"Future Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0029","unstructured":"U.S Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics guidance for industry. https:\/\/www.fda.gov\/media\/71195\/download (2018). (accessed December 2022)."},{"key":"10.1016\/j.cllc.2023.02.002_bib0030","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/14737140.2017.1316196","article-title":"Surrogate endpoints for overall survival in lung cancer trials: a review","volume":"17","author":"Fiteni","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cllc.2023.02.002_bib0031","doi-asserted-by":"crossref","first-page":"S1107","DOI":"10.1016\/j.jtho.2021.08.516","article-title":"P48.05 is relapse-free survival at 2-years an appropriate surrogate for overall survival at 5-years in EGFR-mutated resected NSCLC?","volume":"16","author":"Garcia","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0032","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","article-title":"Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a reanalysis of meta-analyses of individual patients' data","volume":"14","author":"Mauguen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0033","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2017.11.014","article-title":"Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review","volume":"123","author":"Savina","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0034","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1200\/JCO.2008.16.4855","article-title":"Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups","volume":"26","author":"Strauss","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.02.002_bib0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejcts.2004.03.041","article-title":"Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial","volume":"26","author":"Waller","year":"2004","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2023.02.002_bib0036","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423000207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423000207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:35Z","timestamp":1761506075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1525730423000207"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.02.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2\u2013IA3 EGFR-Mutated NSCLC: ADAURA2","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}